ClinicalTrials.gg
CompletedNCT04740840Updated Feb 5, 2021

Anti Inflammatory Treatment of Hypertension

A Phase 2/3 interventional study of Levamlodipine and Amlodipine in Hypertension, sponsored by Affiliated Hospital of North Sichuan Medical College. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-05.

Sponsored by Affiliated Hospital of North Sichuan Medical College · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Registered 10 years 9 months after the study started (first participant enrolled May 2010, registered Feb 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 11 studies testing levamlodipine in Hypertension — none open to participants now, none under way, none of them phase 3. levamlodipine · Hypertension.

Enrollment
2nd of 11
200 · median 63
Started
2010
with 1 other
Phase 2/3
Only one
of the 11
Registered
6th of 11
by date
Lead sponsor
1 of 11
Affiliated Hospital of North Sichuan Medical College

Among the 11 studies testing levamlodipine in Hypertension, this one is the 2nd largest by enrollment, is one of 2 that started in 2010, is the only one in phase 2/3, and was the 6th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.

Browse Hypertension studies →

Open to participants now

None of the 11 studies testing levamlodipine in Hypertension is open now. The open studies under Hypertension, anywhere →

About levamlodipine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing levamlodipine in Hypertension as a file.
02

Study summary

To investigate the anti-inflammatory effect of amlodipine and levamlodipine in the treatment of hypertension

Read the detailed description

A total of 200 inpatients or outpatients in the Department of cardiovascular medicine of the third people's Hospital of Mianyang City from April 2021 to October 2021, who met the diagnostic criteria of ish2020 international hypertension practice guidelines, were selected and randomly divided into control group and experimental group, with 100 cases in each group. The control group was treated with amlodipine and the experimental group was treated with levoamlodipine. The changes of blood pressure and serum inflammatory factors were observed before and after treatment.

03

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • Levamlodipine
  • Amlodipine
  • Serum inflammatory factors
  • Anti inflammatory treatment
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ① In line with the diagnostic criteria of ISH2020 International Guidelines for Practice of Hypertension ② Age >18 years old, gender is not limited, during the treatment did not take other drugs that will affect blood pressure: such as antidepressants, oral , Chinese herbal medicine, etc.; Voluntary participation and signing of , and can complete all the visit plan.

Exclusion criteria

Exclusion Criteria:

  • (1) Those who do not want to take blood tests; (2) \< 50%, heart rate \<50 beats/min; ③ Acute coronary syndrome (unstable angina pectoris and myocardial infarction); ④ valvular heart disease, congenital heart disease, etc.; Other infectious diseases and malignant tumors; ⑥ Bronchial asthma; ⑦ Abnormal liver function and renal dysfunction ( BBB 0 80U/L, CR BBB 1 442mmol/L); diseases or any serious and fatal diseases; ⑨ Receiving lipid-lowering therapy and oral vitamins or antioxidants; They are mentally ill, have no self-awareness, and are unable to express themselves or cooperate with others.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
200 participants (actual)

Study arms

  • Experimental
    Levamlodipine group

    Blood pressure lowering therapy with 2.5mg levamlodipine, plus metoprolol succinate

    Drug: Levamlodipine

  • Sham comparator
    Amlodipine group

    To receive 5mg amlodipine to lower blood pressure, plus metoprolol succinate

    Drug: Amlodipine

Interventions

  • According to the inclusion criteria of the trial, those who met the diagnosis of hypertension were randomly divided into the experimental group and the control group. The experimental group was treated with 2.5mg levamlodipine to lower blood pressure. Abdominal blood was emptying before the start of the trial and at the first and third month of medication.Data on CRP, TNF-α, IL-6, Lp-PLA2 and ATP were collected.

  • DrugAmlodipine

    According to the inclusion criteria, patients who met the diagnosis of hypertension were randomly divided into the experimental group and the control group. The experimental group was given 5mg amlodipine to lower blood pressure. Fasting blood was collected before the trial and during the first and third months of treatment. CRP, TNF-α, IL-6, Lp-PLA2 and ATP data were collected.

06

What researchers measure

Primary outcomes

  1. After treatment, the blood pressure control of L-amlodipine group was better than that of amlodipine group

    Time frame: One month after treatment

  2. the serum inflammatory factor level of L-amlodipine group was lower than that of amlodipine group

    Time frame: One month after treatment

  3. Serum ATP level can be used to evaluate the anti-inflammatory effect of hypertension drugs

    Time frame: One month after treatment

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2010 to primary completion in Apr 2012, 23 months.

Of 15 phase 2/3 interventional studies under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's 23 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2021
First posted
Feb 5, 2021
StartActual
May 1, 2010
Primary completionActual
Apr 2, 2012
CompletionActual
May 2, 2015
Last update
Feb 5, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04740840
Lead sponsor
Affiliated Hospital of North Sichuan Medical College
Collaborators
First Hospitals affiliated to the China PLA General Hospital
Responsible party
Sponsor
First posted
Feb 5, 2021
Start date
May 1, 2010
Primary completion
Apr 2, 2012
Completion
May 2, 2015
Last update
Feb 5, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Levamlodipine

Start the discussion